[Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Cardiotoxicity and extravasation injuries are extremely serious complications of anthracycline use. Both complications are probably caused by oxidative stress. Dexrazoxane has been approved as a cardioprotective agent and as an antidote in extravasation of anthracyclines. Randomized clinical trials have shown that dexrazoxane is the only cardioprotective agent proven to be effective in the treatment of anthracycline-induced cardiotoxicity. In these clinical studies dexrazoxane decreased the incidence of cardiac events and heart failure. Possible adverse effects of dexrazoxane when administered as a cardioprotective agent are a decreased antitumor effect of anthracyclines and the onset of secondary malignancies in children. As an antidote in anthracycline extravasation, clinical studies showed dexrazoxane to be highly efficacious in preventing the need for surgical resection. Dexrazoxane can be considered as the treatment of first choice for this indication. Dexrazoxane is well tolerated in general. The most commonly reported side effects are leukopenia, thrombocytopenia and local reactions at the infusion site.
Goey
Andrew K L
AK
Universiteit Utrecht, Bèta Faculteit, afd. Farmaceutische Wetenschappen, divisie Biomedische Analyse, sectie Drug Toxicology, Utrecht, the Netherlands. A.K.L.Goey@uu.nl
Schellens
Jan H M
JH
Beijnen
Jos H
JH
Huitema
Alwin D R
AD
D018943:Anthracyclines / Q000009:adverse effects* / Q000627:therapeutic use; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D006331:Heart Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D006333:Heart Failure / Q000517:prevention & control; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D011929:Razoxane / Q000627:therapeutic use*
D018943:Anthracyclines; D002317:Cardiovascular Agents; D011929:Razoxane